Momenta Pharmaceuticals Inc (MNTA): Bruce Leicher , SVP & General Counsel of Momenta Pharmaceuticals Inc sold 1,050 shares on Feb 22, 2017. The Insider selling transaction was reported by the company on Feb 24, 2017 to the Securities and Exchange Commission. The shares were sold at $15.60 per share for a total value of $16,380.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 14, 2017, Ganesh Venkataraman Kaundinya (Senior V.P., Research) sold 1,756 shares at $18.90 per share price.On Feb 14, 2017, Bruce Leicher (SVP & General Counsel) sold 1,620 shares at $18.90 per share price.Also, On Feb 14, 2017, Craig A Wheeler (President) sold 7,088 shares at $18.85 per share price.On Dec 16, 2016, Richard P Shea (SVP, CFO) sold 9,799 shares at $15.00 per share price.
Shares of Momenta Pharmaceuticals (MNTA) ended Wednesday, Feb 22, 2017 session in red amid volatile trading. The shares closed down -0.95 points or -5.92% at $15.1 with 14,58,995 shares getting traded. Post opening the session at $16, the shares hit an intraday low of $15.1 and an intraday high of $16.05 and the price vacillated in this range throughout the day. The company has a market cap of $1,077 M and the number of outstanding shares has been calculated to be 7,13,12,626 shares. The 52-week high of Momenta Pharmaceuticals is $19.9 and the 52-week low is $7.86.
Company has been under the radar of several Street Analysts.Momenta Pharmaceuticals is Downgraded by Leerink Partners to Mkt Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Feb 22, 2017.Momenta Pharmaceuticals is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 20 from a previous price target of $19 .The Rating was issued on Jan 31, 2017.
Momenta Pharmaceuticals Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics Biosimilars and Novel Therapeutics. The Companys product a generic version of Lovenox (enoxaparin sodium injection) was approved by the United States Food and Drug Administration. The Company is developing Complex Generics such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars including M923 and M834. The Company is developing Novel Therapeutics including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923 a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.